Cargando…
Development and external validation of a multivariable [(68)Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer
PURPOSE: To develop and evaluate a lymph node invasion (LNI) prediction model for men staged with [(68)Ga]Ga-PSMA-11 PET. METHODS: A consecutive sample of intermediate to high-risk prostate cancer (PCa) patients undergoing [(68)Ga]Ga-PSMA-11 PET, extended pelvic lymph node dissection (ePLND), and ra...
Autores principales: | Muehlematter, Urs J., Schweiger, Lilit, Ferraro, Daniela A., Hermanns, Thomas, Maurer, Tobias, Heck, Matthias M., Rupp, Niels J., Eiber, Matthias, Rauscher, Isabel, Burger, Irene A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382335/ https://www.ncbi.nlm.nih.gov/pubmed/37261472 http://dx.doi.org/10.1007/s00259-023-06278-1 |
Ejemplares similares
-
What’s behind (68)Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns
por: Rüschoff, Jan H., et al.
Publicado: (2021) -
Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with (68)Ga-PSMA-11-PET
por: Ferraro, Daniela A., et al.
Publicado: (2020) -
(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016) -
[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021) -
Performance of [(68)Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2021)